Combined analysis of 3 early-phase trials in 10 patients with previously treated HER2-positive salivary gland cancer: with zanidatamab monotherapy (n=9), confirmed ORR was 44% and median PFS 10.1 months; related AEs were all grade 1/2.
Meta-analysisn = 10
Lee et al. Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies